Published in Transplantation on February 01, 1988
The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant (2011) 1.98
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol (1993) 1.05
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation (2000) 0.95
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl (2001) 0.93
Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers. Transplant Proc (1989) 0.91
Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl (2014) 0.85
Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol (2004) 0.83
Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology (1995) 0.83
The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us? Transplant Proc (1995) 0.82
Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl (2014) 0.78
Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc (1999) 0.76
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (1989) 3.83
MELD and PELD: application of survival models to liver allocation. Liver Transpl (2001) 3.76
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology (1980) 3.57
Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion (1985) 3.35
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med (1997) 2.38
A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant (2006) 2.37
Current concepts. Primary sclerosing cholangitis. N Engl J Med (1984) 2.35
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther (1997) 2.33
Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl (2000) 2.27
Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology (1998) 2.26
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology (1994) 2.10
Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion (1992) 2.07
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. Chest (1990) 1.99
Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med (1987) 1.98
NotI genomic cleavage map of Escherichia coli K-12 strain MG1655. J Bacteriol (1992) 1.96
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc (1989) 1.93
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant (2008) 1.86
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther (1996) 1.83
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology (1990) 1.76
Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology (1995) 1.74
A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. J Infect Dis (1995) 1.71
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc (1988) 1.71
Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum (1988) 1.70
Detection of cytomegalovirus DNA in sera of liver transplant recipients. J Clin Microbiol (1994) 1.69
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology (1990) 1.69
Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis (1983) 1.68
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. Ann Surg (1993) 1.63
Hypotensive reactions: are they a new phenomenon? Are they related solely to transfusion of platelets? Does filtration of components play a role? Transfusion (1996) 1.62
Choledochocholedochostomy, a relatively safe procedure in orthotopic liver transplantation. Surgery (1985) 1.61
Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc (1994) 1.59
Clinical and radiologic features of cerebral edema in fulminant hepatic failure. Mayo Clin Proc (1995) 1.59
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57
Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology (2000) 1.55
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology (1997) 1.54
DR human leukocyte antigens and disease severity in chronic hepatitis C. J Hepatol (1996) 1.54
Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology (1993) 1.53
Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51
Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion (1993) 1.49
Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology (1983) 1.49
Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol (1997) 1.49
Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology (1999) 1.49
Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl (2001) 1.48
Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol (1997) 1.47
Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology (1998) 1.46
Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology (1992) 1.46
Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest (1981) 1.46
A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc (2000) 1.45
Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation (1996) 1.44
Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. Mayo Clin Proc (1994) 1.43
The autologous mixed lymphocyte reaction in primary biliary cirrhosis: analysis of activation and blastogenesis of autoreactive T lymphocytes. Hepatology (1988) 1.43
Retracted Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology (1992) 1.43
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology (1986) 1.43
Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol (1998) 1.43
Nutritional support for liver transplantation: identifying caloric and protein requirements. Mayo Clin Proc (1994) 1.42
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
The role of portosystemic shunts for variceal bleeding in the liver transplantation era. Arch Surg (1994) 1.40
Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol (2000) 1.40
Morning admission to the hospital for surgery the same day. A practical problem for the blood bank. Transfusion (1987) 1.39
Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis (1995) 1.39
The natural history of untreated focal allograft rejection in liver transplant recipients. Liver Transpl Surg (1996) 1.38
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl (2001) 1.38
Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol (1985) 1.34
Increased waiting time for liver transplantation results in higher mortality. Transplantation (1997) 1.34
Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology (1985) 1.34
Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol (1996) 1.31
Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol (1993) 1.29
RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota. Transfusion (2001) 1.28
D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant (2008) 1.27
Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol (1988) 1.26
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology (1999) 1.26
Delayed hemolytic transfusion reactions. Evidence of the need for an improved pretransfusion compatibility test. Am J Clin Pathol (1980) 1.24